Skip to main content


John F. McLaughlin, MD

John F. McLaughlin, MD

Developmental Pediatrics, Pediatrics-Inpatient

On staff since May 1977

Academic Title: Professor Emeritus, University of Washington

"Children and families inspire me. Teams of dedicated colleagues across many disciplines support me. Inquisitive students and trainees keep me honest. Opportunities for new understanding and improved care challenge me. It is a privilege to practice evidence-based medicine in the context of relationships based on trust and mutual respect."


Board Certification(s)
Developmental-Behavioral Pediatrics
Neurodevelopmental Disabilities
Medical/Professional School
Northwestern University Medical School, Chicago
Clinical Interests

Cerebral palsy, spina bifida, developmental disabilities, spasticity/dystonia, interdisciplinary training

Research Description

I am pursuing a research agenda aimed at improving the lives of children and youth with developmental disabilities, especially the management of spasticity and other movement disorders in cerebral palsy. The paradigm is based on the International Classification of Function (ICF) developed by the World Health Organization. The ICF uses an interactive model of human function that takes into account the impact of genetics, neurophysiology, environment, social and personal factors on the ability of individuals to function in age-appropriate roles in human society.

I have a registry of patients who have undergone treatments for spasticity, and participate in an industry-sponsored registry to track the effectiveness of implantable medical devices. I am site PI on a NIH-funded contract to establish whether or not oral baclofen is an effective treatment for spasticity in children with cerebral palsy. I am interested in collaborating with other investigators in this and related areas. Our research team has had two previous NIH RO-1s and other foundation and industry supported grants.

Research Focus Area

Chronic Conditions / Special Health Care Needs, Neuroscience / Neurodevelopment

Awards and Honors

Award NameAward DescriptionAwarded ByAward Date
Lifetime Achievement AwardAmerican Academy for Cerebral Palsy and Developmental MedicineOct. 13, 2013


Population Pharmacokinetics of Oral Baclofen in Pediatric Patients with Cerebral Palsy
Journal of Pediatrics , Jan. 1, 2014
Practice Parameter: Pharmacological Treatment of Spasticity in Children and Adolescents with Cerebral Palsy (an evidence-based revoew). Report of the Quality standards Subcommittee of the american Academy of Neurology and the Practice Committee of the Child Neurology Society.
Neurology , 2010: 74336-343
Sexual functioning in adolescents and young adults with spina bifida.
Archives of physical medicine and rehabilitation , Jan. 2008: 31-5
The relationship of activity capacity and performance to self-reported health status and quality of life in youth with cerebral palsy.
Pediatric Physical Therapy , 2008: 20247-253
Botulinum toxin for spasticity in children with cerebral palsy: a comprehensive evaluation.
Pediatrics , July 2007: 49-58
Ambulatory physical activity performance in youth with cerebral palsy and youth who are developing typically.
Physical Therapy , March 2007: 248-57
GMFM 1 year after continuous intrathecal baclofen infusion.
Pediatric rehabilitation , July 2005: 207-13
Lower extremity sensory function in children with cerebral palsy.
Pediatric rehabilitation , Jan. 2005: 45-52
Hip status in cerebral palsy after one year of continuous intrathecal baclofen infusion.
Pediatric neurology , March 2004: 163-8
Oral motor, communication, and nutritional status of children during intrathecal baclofen therapy: a descriptive pilot study.
Archives of physical medicine and rehabilitation , April 2003: 500-6
Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin.
Journal of neurosurgery , Feb. 2003: 291-5
Long-term safety and efficacy of continuous intrathecal baclofen.
Developmental medicine and child neurology , Oct. 2002: 660-5
Comparison of functional outcomes from orthopedic and neurosurgical interventions in spastic diplegia.
Neurosurgical focus , Jan. 1998: e2
Population pharacokinetic analyis of oral baclofen in pediatric patients with cerebral palsy.

Research Funding

Grant TitleGrantorAmountAward Date
Pediatric Hemiplegia: Synergistic Treatment Using Repetitive Transcranial Magnetic Stimulation and Constraint Induced TherapyInstitutes of Health, ARRA Challenge Grant $421,919.00Sept. 1, 2009
Baclofen for Spasticity TrialNational Institutes of Health $575,000.00July 1, 2006
Infusion System Performance RegistryMedtronic, Inc. $5,000.00March 1, 2006
Improving Measurement of Pain and Fatigue in Children and Adults with disabilitiesNational Institute of Health $787,501.00Sept. 1, 2004
The Effect of Dynamic Ankle-Foot Orthotics (DAFO) in Children with Cerebral PalsyChildren’s Hospital and Regional Medical Center 1998 Research Endowment Support $13,460.00Dec. 1, 1998
Botulinum Toxin for Spasticity in Cerebral PalsyNational Institutes of Health $490,163.00July 1, 1997

Primary Office

Seattle Children's
OC.9.840 - Neurodevelopmental
4800 Sand Point Way NE
Seattle, WA 98105

Additional Offices

University of Washington
UW Box 357920 - CHDD
1959 NE Pacific St
Seattle, WA 98195-7920

Find a Doctor or Researcher

Find a Doctor or Researcher

Type the first or last name you are searching for or select a specialty.

Doctor or Researcher Name:

More search options